Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Post-hoc analysis of the DAPA-HF trial found that the benefit of dapagliflozin for cardiovascular events or worsening heart failure was consistent across background therapies (e.g. diuretics, digoxin, mineralocorticoid receptor antagonists, ivabradine, ACEi & ARB, beta-blocker).
Source:
European Heart Journal